Table 2.

Multivariable analysis of FGFR2 and TACC2 for low-grade breast cancer risk

Gene	SNP	Adjustmentsa	OR (95% CI)	P-value
(a) Single SNP analysis
TACC2	rs17550038		1.24 (1.16–1.33)	4.2 × 10−10
	rs2461211		1.14 (1.09–1.19)	4.8 × 10−10
	rs2461210		1.14 (1.09–1.18)	7.1 × 10−10
	rs7898269		1.16 (1.09–1.22)	2.1 × 10−7
	rs12146254		1.15 (1.08–1.21)	1.3 × 10−6
	rs10887047		1.14 (1.08–1.21)	2.2 × 10−6
(b) FGFR2 2-SNP analysis
	rs2981579	rs78985527	1.33 (1.30–1.37)	8.3 × 10−106
	rs78985527	rs2981579	1.12 (1.06–1.18)	5.7 × 10−5
(c) TACC2 + FGFR2 3-SNP analysis
TACC2	rs17550038	rs2981579, rs78985527	1.14 (1.07–1.23)	1.1 × 10−4
	rs2461211	rs2981579, rs78985527	1.08 (1.04–1.13)	2.1 × 10−4
	rs2461210	rs2981579, rs78985527	1.12 (1.04–1.12)	2.6 × 10−4
	rs7898269	rs2981579, rs78985527	1.10 (1.04–1.16)	1.3 × 10−3
	rs12146254	rs2981579, rs78985527	1.09 (1.03–1.15)	3.2 × 10−3
	rs10887047	rs2981579, rs78985527	1.08 (1.03–1.15)	4.2 × 10−3
FGFR2	rs2981579	rs17550038, rs78985527	1.32 (1.29–1.36)	1.3 × 10−100
	rs2981579	rs2461211, rs78985527	1.33 (1.29–1.36)	1.7 × 10−100
	rs2981579	rs2461210, rs78985527	1.33 (1.29–1.36)	1.2 × 10−100
	rs2981579	rs7898269, rs78985527	1.33 (1.29–1.36)	2.8 × 10−102
	rs2981579	rs12146254, rs78985527	1.33 (1.30–1.37)	8.8 × 10−103
	rs2981579	rs10887047, rs78985527	1.33 (1.30–1.37)	7.3 × 10−103
FGFR2	rs78985527	rs17550038, rs2981579	1.11 (1.05–1.17)	8.1 × 10−5
	rs78985527	rs2461211, rs2981579	1.11 (1.05–1.17)	1.4 × 10−4
	rs78985527	rs2461210, rs2981579	1.11 (1.05–1.17)	1.5 × 10−4
	rs78985527	rs7898269, rs2981579	1.11 (1.05–1.17)	8.2 × 10−5
	rs78985527	rs12146254, rs2981579	1.11 (1.06–1.18)	5.8 × 10−5
	rs78985527	rs10887047, rs2981579	1.11 (1.06–1.17)	7.4 × 10−5

^aIn addition to study and principal components.